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Abstract
Background: Correlation between circulating sex steroid levels and breast cancer has been controversial, with
measurement of free, or bioavailable hormone rarely available. Salivary hormone levels represent the bioavailable
fraction. To further elucidate the role of endogenous hormones in breast cancer, we aimed to assess correlation
between salivary sex steroid levels and breast cancer prevalence.
Methods: Salivary hormone levels of testosterone (T), Estradiol (E2), Progesterone (P), Estriol (E3), Estrone (E1),
DHEAS and Cortisol (C) were measured by Enzyme Immunoassay (EIA) in 357 women with histologically verified
breast cancer and 184 age-matched control women.
Results: Salivary T and DHEAS levels were significantly lower in breast cancer cases vs. controls (27.2+13.9 vs. 32.2+
17.5 pg/ml, p < 0.001 for T and 5.3+4.3 vs. 6.4+4.5 ng/ml, p = 0.007 for DHEAS). E2 and E1 levels were elevated and
E3 levels were lowered in cases vs. controls.
Conclusions: Salivary T levels, representing the bioavailable hormone, are significantly lower in women with breast
cancer compared to age-matched control women. These findings support the protective role of biovailable
testosterone in counteracting the proliferative effects of estrogens on mammary tissue.
Background
The risk of developing breast cancer is related to events
of reproductive life and lifestyle factors that modify
levels of endogenous sex hormones. Soon after the dis-
covery of sex hormones, it was suggested that breast
cancer risk was related to endogenous estrogen levels.
Recent large prospective cohort studies on postmeno-
pausal women make it clear that high levels of estrogens
increase mammary gland proliferation and are asso-
ciated with increased breast cancer risk [1].
Interestingly, several observations suggest that andro-
gens may counteract the proliferative effects of estrogen
and progestogen in the mammary gland. In cell cultures
and animal experiments, androgens have been shown to
exert anti-proliferative effects [2]. It has also been
demonstrated that a negative association exists between
breast cell proliferation and levels of free testosterone in
both pre- and postmenopausal women [3,4]. However,
the relationship between endogenous androgen levels
(testosterone, androstenedione, dehydroepiandrosterone
(DHEA)) and breast cancer risk is still unclear with both
epidemiologic and experimental data providing conflict-
ing results [5,6]. Many of these studies use inaccurate
methods to measure the low levels of bioactive forms of
androgens in women.
Our aim was to examine whether salivary testosterone
levels were lower in breast cancer patients compared to
the general population. Hypotheses of whether elevated
testosterone levels are associated with elevated estrogen
levels were also investigated. To address this issue a case-
control study was designed. Immunoassay has been used
for the measurement of hormones in saliva, given the
sensitivity, reliability, and serum saliva correlations for
these assays [7,8].
Methods
Salivary hormone levels were collected in 357 newly
diagnosed breast cancer patients between 2001 and
2004. Breast cancer diagnosis was categorized according
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noma), DCIS (ductal carcinoma in situ), ILC (infiltrating
lobular carcinoma) and LCIS (lobular carcinoma in situ,
a risk factor for invasive breast cancer). All patients
were in a single surgical practice of one of us (RG).
Salivary hormone levels were also collected in a group
of 184 controls. These were women who presented with
benign breast disease (benign breast lump, fibrocystic
tissue or breast pain) in the same practice (RG), during
the same time period. Patients with atypical ductal
hyperplasia were excluded from the study.
The two groups (patients and controls) were matched
for breast cancer risk factors such as age, menopause sta-
tus, family history of breast cancer, use of hormone ther-
apy, age at menarche and age at first birth (Table 1).
Breast cancer patients had an average age of 54.8 years
(ranging from 30 up to 86 years) while in the control
group the average age was 53.5 years (31 to 81 years). Two
hundred and thirty eight patients were menopausal
(66.7%), while in the control group 115 women were
menopausal (62.5%). A chi-square test indicated that there
were no statistically significant differences between the
two groups according to age and to menopausal status
(p-value 0.115 and 0.342, respectively). The two groups
were also matched for non-malignancy associated surgical
menopause: 31 out of 184 (16.84%) women in the control
group and 58 out of 357 (16.24%) had a surgical hysterect-
omy with bilateral oophorectomy. About half of the
patients (47.8%) had a family member suffering from
breast or ovarian cancer and this rate was comparable to
the control group (51.7%, chi-square p-value 0.535). Some
women in our study received hormonal treatment, either
estrogen or progesterone or both, but there was no evi-
dence that these rates differ amongst the two groups
(p-value 0.066). Few patients were supplementing with
estradiol, the majority had been on conjugated equine
estrogens. The control group had an average age at
menarche 12.7 years and the case group 12.6 years, while
age at first pregnancy was 24.3 years for the control group
and 23.9 years for breast cancer patients. Graphics and
comparisons are illustrated in Table 1.
Salivary testosterone (T), Estradiol (E2), Progesterone
(P), Estriol (E3), Estrone (E1), dehydroepiandrosterone
sulfate (DHEAS) and cortisol (C) levels were measured
in all women and compared between the two groups
(Table 2). All salivary specimens were evaluated at the
same laboratory (ZRT).
An ethical approval was obtained for this study from
Athens University Medical School and an informed con-
sent was obtained from the subjects. Women were fully
informed on the details of the study and agreed to partici-
pate and have their data published.
Saliva Collection
Because hormone levels vary throughout the day, lead-
ing to inaccuracies in many studies, saliva (minimum
Table 1 Demographics of control vs. breast cancer
patient groups
Controls
(N = 184)
Cases
(N = 357)
p-value
Age 53.5 (+9.7) 54.8 (+12) 0.181
Menopausal pre 69 (37.5%) 119 (33.3%)
status post 115 (62.5%) 238 (66.7%) 0.342
Family negative 72 (48.3%) 175 (52.2%)
history positive 77 (51.7%) 160 (47.8%) 0.535
HRT no 96 (52.2%) 217 (60.8%)
yes 88 (47.8%) 140 (39.2%) 0.066
Age at menarche 12.7 (+1.3) 12.6 (+1.5) 0.319
Age at 1
st pregnancy 24.3 (+4.6) 23.9 (+5.1) 0.503
Age is in years. Standard deviation and percentages are in parenthesis.
P-values were computed using chi-square tests and students t-test.
Table 2 Mean levels of hormone measurements by group
and according to menopausal status
Controls (sd) Cases (sd) p-value
T
pre 34.3 (16.1) 31.4 (15.3) 0.234
post 31.0 (17.6) 25.1(12.6) 0.002
overall 32.2 (17.5) 27.2 (13.9) <0.001
E1
pre 3.8 (2.9) 5.0 (2.9) 0.037
post 3.6 (2.1) 4.8 (4.8) 0.047
overall 3.7 (2.4) 4.9 (4.2) 0.006
E2
pre 2.1 (2.1) 2.4 (2.0) 0.295
post 1.2 (0.8) 1.7 (1.3) <0.001
overall 1.65 (1.3) 2.0 (1.6) 0.005
E3
pre 5.2 (7.3) 2.7 (1.5) 0.001
post 3.7 (2.6) 3.6 (3.8) 0.734
overall 4.3 (4.9) 3.3 (3.3) 0.011
DHEAS
pre 7.3 (4.8) 6.8 (4.9) 0.434
post 5.7 (4.2) 4.5 (3.7) 0.007
overall 6.4 (4.5) 5.3 (4.3) 0.007
T/E1
pre 28.26 (46.7) 8.23 (7.6) <0.001
post 22.97 (79.5) 8.74 (12.9) 0.021
overall 24.75 (68.5) 8.57 (11.4) 0.014
T/E2
pre 19.34 (11.6) 19.90 (23.43) 0.667
post 34.09 (25.5) 25.86 (52.3) 0.063
overall 27.45 (21.7) 23.86 (44.6) 0.212
T/E1 and T/E2, average ratios of testosterone over estrone and estradiol,
respectively. Sd, standard deviation. P-values were computed using students’
t-test. Testosterone (T) pg/ml, Estrone (E1) pg/ml, Estradiol (E2) pg/ml, Estriol
(E3) pg/ml, DHEAS ng/ml.
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Page 2 of 85 ml) was collected in polypropylene tubes in the morn-
ing upon rising and before breakfast (7-9 a.m.). Food
and beverages (except water) were avoided 2 h prior to
saliva collection. Women on hormone replacement ther-
apy (HRT) had discontinued therapy at least one month
prior to salivary hormone collection. Saliva samples
were shipped within 24 h for laboratory analysis.
Saliva Processing
Saliva was processed by adding 50 μlo f0 . 1 4m g / m l
dithiothreitol (DTT) per ml of saliva to break up mucins
that interfere with saliva extraction. Steroids were then
extracted from 1.5 ml of saliva by C-18 column chroma-
tography. Samples were gently pulled through the
columns by vacuum. Control and calibrator samples
were prepared from Biorad Lyphocheck diluted 1/100 in
phosphate-buffered saline (PBS) buffer containing DTT.
The C-18 columns were washed twice with PBS buffer,
vacuum dried, and the steroids eluted with 100% etha-
nol. The eluted solvent containing the steroids was
dried under nitrogen and then reconstituted 2× in PBS
buffer containing 0.1% T904 detergent and 0.05% Pro-
clin antimicrobial (assay buffer).
Steroid Testing
Steroids in the extracted/reconstituted saliva were quan-
tified by enzyme immunoassay (EIA) with commercial
kits from DRG, Germany. Standards were prepared in
assay buffer from a concentrated stock of each hormone
with serial dilution. Inter- and intra-assay coefficients of
variation for low and high controls for all steroids tested
were 10% or less. Ranges were based on gender, age,
menstrual status (e.g. follicular vs. luteal phase of the
menstrual cycle) from greater than 1000 women in each
category.
Statistics
Univariate statistical analysis was performed to address
the questions stated before.
Normality of the data was checked using graphical
investigation (histograms and q-q plots) as well as the
Kolmogorov Smirnov test (results not shown). Student’s
t-test was used to compare the mean hormone levels
while chi-square tests were performed when comparing
frequencies. A simple linear regression was used to illus-
trate graphically the correlation between testosterone
and E1, E2 levels. Also, multivariate analysis was per-
formed to assess the dependency of testosterone levels
on a set of independent variables. All statistical analysis
were performed in an alpha = 5% level.
Results
Table 2 presents steroid hormone measurements for the
two groups. T and DHEAS levels were significantly
lower (15.5% and 17.2%, p-value <0.001 and 0.007,
respectively) in breast cancer patients vs. the control
group. E3 levels were also 23.2% lower in the breast
cancer group (P = 0.01). On the contrary, levels of E2
and E1 were higher in breast cancer patients (17.5% and
24.5%, p-value 0.005 and 0.006, respectively). No statisti-
cally significant differences were found for the levels of
progesterone or cortisol (data not shown). Comparing
the number of breast cancer patients versus controls
with levels of testosterone below normal (< 20 pg/ml),
we have 20.1% of women in the control group and
29.6% of patients, with levels of testosterone lower than
normal (p-value = 0.021).
Menopausal women had, on average, reduced T and
DHEAS levels when compared with premenopausal in
both groups (data not shown). Comparison of salivary hor-
mone levels according to menopausal status (Table 2)
showed that T and DHEA-S levels were markedly lower in
the post-menopausal cancer group vs. post-menopausal
control. (19% and 21% reduction, p-values 0.002 and 0.007
for T and DHEA-S respectively). In pre-menopause,
although levels are lower in patients, it does not reach
statistical significance. On the contrary, E2 levels were
higher in the post-menopausal breast cancer group vs.
post-menopausal controls (29.4% increase, p-value
<0.001), while E1 levels were higher both in pre- and post-
menopausal breast cancer patients.
Ratios of testosterone over E1 and E2 were also com-
puted overall as well as in pre and post menopausal
women (Table 2). Differences of T/E1 are significant
when comparing the two groups overall (p-value 0.014)
as well as the different strata (p < 0.001 and p = 0.021
for pre and post-menopausal women, respectively).
When comparing the ratio of testosterone over E2 no
significant differences could be found.
Mean levels of hormones were compared in breast
cancer cases according to the histology type of the
excised tumor: infiltrating ductal or lobular carcinoma
(IDC/ILC)] or ductal carcinoma in situ (DCIS). Results
are shown in Table 3. No statistically significant differ-
ences were found.
To assess whether breast cancer patients with higher
testosterone levels have corresponding higher E1 levels,
a scatter plot was created. In Figure 1, measurements
taken from both cancer and control groups are pre-
sented. It shows that there is a positive correlation
between testosterone and E1 levels in breast cancer
patients. This means that as testosterone levels increase
in breast cancer patients, E1 levels tend to increase as
well. The opposite holds for controls, in which the
regression line has a decreasing slope, showing that as
testosterone levels increase, E1 levels tend to decrease.
Spearman’s correlation coefficient was 0.159 (p-value
0.012) for cases and -0.030 (p-value 0.749) for controls.
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one and E2 levels. In both cases and controls there is a
positive correlation as indicated from the regression
lines (Spearman’s correlation coefficient 0.425 in control
group and 0.249 in cases group, p-values <0.001 in both
groups). There is also a positive correlation between E1
and E2 levels (data not shown).
A multivariate linear model was used to assess the
dependency of Testosterone levels on a set of indepen-
dent variables (Table 4). It was found that testosterone
levels are significantly related to age (p-value 0.017), to
the group that each subject belongs to (cases or con-
trols, p-value <0.001), to E2 levels (p-value <0.001) and
to progesterone levels (p-value 0.03). Looking at the
values of coefficients it can be seen that testosterone
levels increase by 2.78 as E2 increases, while similar
positive association can be seen with progesterone. On
the other hand, as age increases the levels of testoster-
one are dropping by 0.14 on average.
Discussion
This study has shown for the first time that endogenous
bioavailable testosterone levels are lower in women with
breast cancer vs. relevant control women. Although
Table 3 Average levels of hormones according to
histology type
Cases (sd) p-value
Testosterone
IDC/ILC 27.8 (14.4)
DCIS 24.8 (11.3) 0.146
E1
IDC/ILC 5.21 (4.5)
DCIS 4.15 (3.3) 0.162
E2
IDC/ILC 2.09 (1.5)
DCIS 1.70 (1.2) 0.132
E3
IDC/ILC 3.55 (3.5)
DCIS 3.33 (2.3) 0.976
DHEAS
IDC/ILC 5.38 (4.3)
DCIS 5.03 (4.4) 0.585
IDC, infiltrating ductal carcinoma, ILC, infiltrating lobular carcinoma, DCIS,
ductal carcinoma in situ. IDC/ILC, 298 cases, DCIS, 53 cases, 6 cases were
missing. Sd, standard deviation.
Testosterone pg/ml, Estrone (E1) pg/ml, Estradiol (E2) pg/ml, Estriol (E3) pg/ml,
DHEAS ng/ml.
Figure 1 Regression of testosterone on E1. Cases are plotted as black circles while controls as red. Regression line equation for controls:
E1 = 4.256+0.012* Testosterone, R
2 = 0.003 p-values <0.001, 0.532 for constant and beta1, respectively. Regression line equation for cases: E1 =
3.662+0.046*Testosterone, R
2 = 0.025 p-values <0.001, 0.017 for constant and beta1, respectively. E1, pg/ml, Testosterone, pg/ml.
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Page 4 of 8saliva has not yet become a mainstream sample source
for hormone analysis, it is a valuable research tool offer-
ing a non-invasive and stress-free alternative to plasma
and serum. It has proven to be reliable and in some
cases superior to other body fluids demonstrating a very
close correlation with free testosterone levels in serum
[9]. Saliva has several advantages over blood as a sam-
pling medium: it can be easily collected by subjects
themselves at repeated intervals; it requires no special
collection or storage equipment; and the steroid concen-
trations measured exclude the fraction tightly bound to
serum proteins and thus unavailable for biological action
[8,10]. Testosterone serum levels have limited reliability
in the low ranges found in normal women [11] and they
vary widely based on genetic, metabolic and endocrine
influences [12]. It is now accepted that measurements of
free or bioavailable testosterone predicts androgenic
effects more accurately than total testosterone levels.
For the accuracy of our study, all samples were collected
at the same time of the day. Early morning collections
ensure measurement of the higher diurnal testosterone
levels in all individuals.
Our findings that estrogens are related to individual
breast cancer risk both premenopausally and postmeno-
pausally are generally consistent with former studies
[13-16]. In line with other authors, we report higher
concentrations of estrogens being associated with
increased breast cancer risk both in pre- and post-
menopausal women [16,17]. Estrone and Estradiol mean
levels were elevated in both pre and post menopausal
patients; however E2 does not reach statistical signifi-
cance in the pre-menopausal group. The latter was not
unexpected given that we assessed only free estradiol
levels in saliva. Free estradiol is the most potent circu-
lating estrogen, and it is usually presenting only minimal
variation [18]. Because of its highly activating potential,
Figure 2 Lines represent regression of testosterone on E2. Cases are plotted as black circles while controls as red. Regression line equation
for controls: E2 = 1.002+0.02* Testosterone, R
2 = 0.181 p-values 0.235, <0.001 for constant and beta1, respectively. Regression line equation for cases:
E2 = 1.212+0.028*Testosterone, R
2 = 0.061 p-values <0.001, <0.001 for constant and beta1, respectively. E2, pg/ml, Testosterone, pg/ml.
Table 4 Multivariate analysis showing the dependency of
testosterone on a set of independent variables
Age -0.135 0.017
Group -5.580 <0.001
E2 2.381 <0.001
progesterone 0.001 0.03
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Page 5 of 8estradiol levels tend to be preserved almost invariably in
each woman by highly sophisticated mechanisms like
FSH feedback and SHBG levels. Significant differences
of activated E2 levels could induce acute symptoms
mimicking menarche or menopause and breast and
endometrial cancers that are considered result of
prolonged estrogenic action. Estriol seems to be breast
cancer protective since it was found elevated in pre-
menopausal controls vs. breast cancer patients. It has
been reasoned that the principal pregnancy estrogen
estriol and other pregnancy hormones are not associated
with a risk of breast cancer [19] and they may also
reduce breast cancer risk later in life [20].
There are conflicting data on the association between
androgen levels and breast cancer risk [21]. Some retro-
spective, epidemiologic studies using inaccurate meth-
odologies to measure testosterone have shown an
increased incidence of breast cancer associated with ele-
vated testosterone levels. Also, androgens can stimulate
t h eb r e a s ti n d i r e c t l yb yp r o v i d i n gt h em a j o rs u b s t r a t e
for the synthesis of estrogens in peripheral or mammary
adipose tissue. However, other studies have shown a
decreased risk or no difference [3,4,17]. Using an accu-
rate methodology, we report lower testosterone and
DHEAS levels in breast cancer patients vs. controls indi-
cating a lower androgen production in breast cancer
patients than in healthy individuals. In addition, when
taking the level of 20 ng/dl as the lower normal value of
testosterone, there were more breast cancer patients
than controls with levels below normal values.
Evidence suggests that the fall in androgen production
begins as early as the third decade in women, with a gra-
dual decline thereafter [6]. We found that T levels are
significantly related to age and as age increases, the levels
of T are dropping by 0.14 on average. As expected, T and
DHEAS levels in our study are influenced by the meno-
pausal status with menopausal women having, on aver-
age, reduced levels compared with premenopausal
women, an observation that is in accordance with pub-
lished literature [22]. Since the mechanism of hormone
production changes dramatically after menopause, the
two groups were stratified according to menopausal sta-
tus. According to this stratification, postmenopausal
breast cancer patients present with lower T and DHEAS
levels when compared to controls. The same happens
with premenopausal women; however, this difference
was not statistically significant. Thus, the overall lower
androgen levels in patients with breast cancer could be
attributed to the subgroup of post-menopausal women,
suggesting that breast cancer risk augments post-
menopausally as testosterone levels decline.
One may argue that there are some breast cancer
patients in our study with high androgen levels and some
healthy individuals with low levels. We believe that
higher testosterone levels are generally associated with
higher estrogen levels since androgens are the substrate
for conversion to estrogens. This could explain the posi-
t i v ea s s o c i a t i o ni ns o m es t u dies between breast cancer
and testosterone where, this association was no longer
significant after adjusting for estrogens [23,24]. In our
study, breast cancer patients with high testosterone levels
have also higher estrogen levels (Figure 1, 2). There is a
positive correlation between T and E1 or E2 levels in
breast cancer patients. In other words, as T levels
increase in patients, estrogen levels increase as well. On
the contrary, higher T levels in control patients are asso-
ciated with lower E1 levels. In addition, in a multivariate
analysis, T levels are significantly related not only to age
but to E2 levels as well. The above observations could
mean that higher testosterone concentration proved
insufficient to inhibit tumorinogenesis in presence of
high estrogen levels. Our findings are not in contrast
with the hypothesis of Liao et al. who proposed that con-
comitant elevation in both androgens and estrogens may
confer a greater risk for mammary gland tumorigenesis
than the elevation of each hormone alone [25].
It is has also been suggested that the balance between
the stimulatory effect of estrogens and the inhibitory
effect of androgens is the critical factor that regulates
mammary cell proliferation both in normal and in can-
cer tissues [22]. In support of these observations, the
T/E1 ratio in our study was lower in breast cancer cases
when compared to controls overall, pre and post-meno-
pausally. The exact concentrations of estrogens and
androgens in the breast and their intracrinological regu-
lation not completely clear, nor is the fragment of the
circulating androgens that may reflect the mammary
tissue effective ‘hormone load’ [4,22,26].
Unlike other studies [27,28], no correlation was found
between tumor histology and hormone levels. Testoster-
one and estrogen levels did not differ between in-situ
and invasive carcinoma. It could mean that hormone
imbalance is crucial for carcinogenesis and not for
tumor progression.
A major weakness of the present study is that body
mass index (BMI) was not reported. However, the rela-
tionship of adiposity with breast cancer especially in
postmenopausal women could be partially explained by
the increases in endogenous estrogens [29], and not by
a decrease in biovailable androgens. The risk decreases
after adjustment to estrogens but not to androgens [30].
Our findings are in agreement with clinical and
experimental observations suggesting that androgens
counteract the proliferative effects of estrogens on the
mammary gland and are considered to be protective
against estrogenic carcinogenesis [3,4,31,32]. In the pre-
sent study, bioavailable testosterone levels in breast can-
cer patients were found to be statistically significantly
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Page 6 of 8lowered compared to non-cancer controls, supporting
the hypothesis of an ‘androgen-protection deficiency’
occurring in breast cancer patients.
Conclusions
Salivary testosterone levels are significantly lower in
breast cancer patients compared to controls. These dif-
ferences are more profound in postmenopausal women.
Salivary E1 and E2 levels were elevated in cases leading
to a lower T/E1 ratio in breast cancer patients compar-
ing to healthy individuals.
Our results support a correlation between endogenous
androgen and estrogen levels and breast cancer risk.
Breast cancer patients appear to have a relative imbal-
ance of sex steroid hormones in favor of estrogens.
Higher biovailable testosterone may counteract the pro-
liferative effects of estrogens on mammary tissue and
may exert a protective role to the breast, inhibiting can-
cer development and/or tumor growth.
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